2140911-49-3
2140911-49-3 structure
- Name: OAB-14
- Chemical Name: OAB-14
- CAS Number: 2140911-49-3
- Molecular Formula: C32H46N4O2
- Molecular Weight: 518.73
- Catalog: Research Areas Neurological Disease
- Create Date: 2022-04-14 19:27:09
- Modify Date: 2025-08-20 18:28:42
-
OAB-14, is a Bexarotene (HY-14171) derivative, improves Alzheimer's disease-related pathologies and cognitive impairments by increasing β-amyloid clearance in APP/PS1 mice. OAB-14 effectively ameliorates the dysfunction of the endosomal-autophagic-lysosomal pathway in APP/PS1 transgenic mice[1][2].
| Name | OAB-14 |
|---|
| Description | OAB-14, is a Bexarotene (HY-14171) derivative, improves Alzheimer's disease-related pathologies and cognitive impairments by increasing β-amyloid clearance in APP/PS1 mice. OAB-14 effectively ameliorates the dysfunction of the endosomal-autophagic-lysosomal pathway in APP/PS1 transgenic mice[1][2]. |
|---|---|
| Related Catalog | |
| In Vivo | OAB-14 significantly alleviates cognitive impairments in amyloid precursor protein (APP)/presenilin 1 (PS1) transgenic mice after administration for 15 days or 3 months. OAB-14 rapidly cleared 71% of Aβ by promoting microglia phagocytosis and increasing IDE and NEP expression. OAB-14 also attenuates the downstream pathological events of Aβ accumulation, such as synaptic degeneration, neuronal loss, tau hyperphosphorylation and neuroinflammation in APP/PS1 mice. OAB-14 has no significant effect on body weight or liver toxicity after acute and chronic treatment[1]. OAB-14 facilitates receptor-mediated endocytosis and restores autophagy flux via the AMPK/mTOR pathway. OAB-14 enhances the lysosomal activity, and reduced Aβ accumulation in lysosomes is observed in OAB-14-treated AD mice[2]. |
| References |
| Molecular Formula | C32H46N4O2 |
|---|---|
| Molecular Weight | 518.73 |